XtalPi Holdings Limited's 2026 interim results reveal strong growth in AI4S Intelligent Solutions despite overall revenue fluctuations. The company details advancements in its AI drug R&D platform, pipeline development, and a self-evolving AI retrosynthesis system, underscoring its role in accelerating scientific discovery.
Comments